This ad will auto close in 10 seconds
Cipla, Godrej recognised in Fortune 'Change the World' list

Cipla, Godrej recognised in Fortune 'Change the World' list

India's pharmaceutical giant Cipla and consumer goods conglomerate Godrej have been recognised by Fortune magazine in a list of global firms changing the world for the good and having a positive social impact through their activities.

Cipla, Godrej Consumer Products in Fortune 'Change the World' list

Two Indian companies -- Cipla and Godrej Consumer Products -- have been named in Fortune magazine's list of top 50 companies that are addressing global social problems as part of their core business strategy.

Lupin Pharmaceuticals is India's most reputed pharma brand; Sun Pharma second

Lupin Pharmaceuticals is India's most reputed pharma brand; Sun Pharma second

Mumbai-based Lupin Pharmaceuticals is India`s most reputed pharmaceutical brand, said a report by Bluebytes, a leading media-analytics company on Wednesday.

FDCs banned over safety & efficacy concerns: Centre tells HC

The hearing in the matter would continue on April 4.  

Delhi High Court to resume hearing on petitions against Centre's ban on drugs

Delhi High Court to resume hearing on petitions against Centre's ban on drugs

Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.

Cipla invests additional $ 3mn in US's Chase Pharmaceuticals

Drug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer's disease.

Antim Baazi: Action In Cairn India, Reliance & Cipla

Check out the action going in Cairn India, Reliance & Cipla.

Cipla sets up 6-member leadership team

Drug major Cipla on Thursday announced the creation of a 6-member 'Management Council' that will be the apex executive leadership team for the company.

Cipla launches generic hepatitis C drug in India

Drug major Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.

Hot Stocks: Expert on Gabriel India, Cipla

Know what our expert has to say about
Zee Business, India's first 24-hour Hindi business channel, was conceived to offer 'information' and 'insight' and bring business and economy coverage to you in your own language.

Cipla infringing Roche's patent in lung cancer drug: HC

In a setback to Cipla, the Delhi High Court on Friday held that the Indian drug major was infringing Swiss pharmaceutical company Hoffman-La Roche's patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva.

Cipla Q2 net profit at Rs 431 crore;lower growth expected in H2

Net sales of the company rose to Rs 3,361.73 crore for in the second quarter of current fiscal.

Cipla to sell entire stake in Biomab Holding for $25,775,000

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant Ltd for a consideration of USD 25,775,000 to focus on biological segment under its arm Cipla BioTec.

Cipla's Indore plant under USFDA scanner over norms violations

Cipla's Indore plant under USFDA scanner over norms violations

Pharmaceutical major Cipla's shares dropped by 2.13 percent Tuesday amid speculation that the company's Indore plant has come under the scanner of US health regulator for manufacturing norms violations.

FIPB to take up 25 FDI proposals on Sept 22

FIPB will take up 25 foreign direct investment (FDI) proposals, including those of Aditya Birla Nuvo, Cipla, Sun Pharma Advanced Research and HDFC Capital Advisors, on September 22.

Cipla gains 3% on strong revenue outlook

Shares of Cipla Friday soared nearly 3 percent in morning trade on bourses after the company said it expects 20 percent growth in revenues in the current fiscal.

Cipla Q1 net profit zooms over two-fold to Rs 651 crore

Drug major Cipla on Friday reported an over two-fold jump in its consolidated net profit to Rs 650.61 crore for the quarter ended June 30, 2015 mainly on account of robust sales.

FIL Capital to invest in Cipla's consumer healthcare biz

Drug major Cipla on Tuesday said its board has approved a potential investment by FIL Capital Investments (Mauritius) II Ltd in its consumer healthcare business.

Cipla heir apparent Kamil Hamied quits, bigger role for sister Samina

Pharmaceuticals major Cipla Chairman Yusuf K Hamied's nephew Kamil Hamied, who has been understood to be groomed to take over the reins of the drug maker, has quit and his sister Samina Vaziralli has assumed an expanded role in the company.

Stempeutics receives ODD in EU for its novel stem cell drug “Stempeucel”

Thromboangiitis obliterans or Buerger's disease is a rare and severe disease affecting the blood vessels of the legs.